Author: Anoma Ranaweera B.V.Sc; PhD (Clinical Biochemistry, University of Liverpool, UK), 2013.
On May 29, 2013, the U. S. Food and Drug Administration (FDA) approved trametinib (MEKINIST™ tablets, GlaxoSmithKline, USA), as a single agent oral treatment for patients with non-operable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations as detected by an FDA-approved test, called the THxID™ – BRAF assay from bioMérieux S.A.
Trametinib is the fourth new cancer drug approved that demonstrates an improvement in overall survival in melanoma patients.
It is not indicated for the treatment of patients who have received a prior BRAF inhibitor therapy such as dabrafenib or vemurafenib.
FDA approval was based on results of the phase III METRIC trial.
The most common adverse reactions (greater than or equal to 10%) of any grade in patients receiving trametinib included:
Key efficacy findings are summarised in the tables below.
|Efficacy parameter||Trematinib (n = 214)||Chemotherapy (n = 108)|
|Median progression-free survival (months)||4.8 (95% confidence interval [CI]: 4.3, 4.9)||1.5 (95% CI: 1.4, 2.7)|
|Overall tumour response rates (% patients)||22% (95% CI: 17, 28)||8% (95% CI: 4, 15)|
|Complete response, n (%)||4 (2%)||0|
|Partial response, n (%)||43 (20%)||9 (8%)|
|Median duration of response (months)||5.5 (95% CI: 4.1, 5.9)||Not reached|
|Trematinib (N = 211)||Chemotherapy (N = 99)|
|All Grades||Grades 3 and 4||All Grades||Grades 3 and 4|
|Skin and subcutaneous tissue disorders|
See the DermNet NZ bookstore
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.